STAT reports that the drug industry’s top lobbying group is attempting to boost its funds in anticipation of a show down with regulators. Clinton recently released a plan for reigning in costs, which was quickly criticized by drug makers, but it is likely that she will “face pressure from the Bernie Sanders wing of the Democratic Party to follow through on her promises.”
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.